The cost of hot new weight-loss drugs could put some companies out of business, Blackstone exec warns

• Execs at a healthcare conference debated whether employers should pay for workers' weight-loss drugs.
• A Blackstone exec warned that the costly GLP-1 drugs could put some employers out of business.
• Panelists agreed that companies covering the drugs should do so as part of a broader support program. 

As more people seek out expensive drugs that help with weight loss, their companies are facing difficult decisions about whether to pay for them.

For some companies, it just doesn't make financial sense, an executive at private equity giant Blackstone said Tuesday during a panel discussion at the HLTH conference in Las Vegas.